Yakup Ergün/X
May 17, 2025, 15:28
Yakup Ergün: Great Debate on Continuing CDK4/6 After Progression
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X:
“ESMO Breast 2025
Great Debate on Continuing CDK4/6 After Progression!
Kevin Kalinsky: Yes, switching ET with CDK4/6i improves PFS (e.g., imunestrant+abemaciclib 9.1 mo). Reasonable option.
Fabrice Andre: No, no meaningful clinical benefit, abemaciclib modest, CDK4/6i not ideal for optimal combos.
What do you think?”
More posts featuring ESMO Breast 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 17, 2025, 15:28
May 17, 2025, 15:15
May 17, 2025, 15:04
May 17, 2025, 15:03
May 17, 2025, 14:56
May 17, 2025, 12:46